Exelixis Inc Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized
Exelixis Inc (EXEL) had Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized of 28.50 million shares as of 2022-05-25, per its 10-Q filed 2022-11-01.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized · last filed 2022-11-01
- 2022-05-25: Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized 28.50M shares.
- 2020-05-20: Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized 21.00M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized |
|---|---|
| 2022-05-25 | 28.50M shares 10-Q · filed 2022-11-01 |
| 2020-05-20 | 21.00M shares 10-K · filed 2022-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |